Bavarian Nordic

A May outbreak of monkeypox, a rare disease mostly seen in Africa, has found at least one European country stocking up on supplies from Danish biotech ...

The illness typically starts off with flulike symptoms and swelling lymph nodes, followed by a rash on the face and body, and usually takes two to four weeks to resolve. Of the 20 cases confirmed across Europe, most reportedly seem to have been acquired locally. The fatality rate is roughly 0% to 10%, and slightly higher among children, WHO said. Dr. Eric Toner, a senior scientist and health security expert with the Johns Hopkins Bloomberg School of Public Health said in the same article that the disease is “not highly transmissible” and unlikely to “cause large outbreaks.” That’s due to monkeypox’s long incubation period, up to 21 days, which offers “plenty of time to implement quarantine and isolation,” he said. Monkeypox has largely been seen in Africa, triggered by infections from rodent and small-animal bites. The U.S. case represents a “public health urgency,” but not emergency, Andrea McCollum, an epidemiologist with the CDC’s poxvirus and rabies branch, is reported to have told Fortune magazine in an article published Thursday. The U.S. saw an outbreak in 2003, caused by a shipment of animals from Ghana, with six Midwest states affected.

Danish vaccine developer Bavarian Nordic (OMX: BAVA) revealed today that it has secured a contract with an undisclosed European country to supply its ...

• Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. • All the news that moves the needle in pharma and biotech. If your trial has come to an end, you can subscribe here.

Bavarian Nordic (BVNKF) (BVNRY) said it secured a contract with an undisclosed European country to supply its Imvanex smallpox vaccine in response to new ...

- Bavarian Nordic (OTCPK:BVNKF) ( OTCPK:BVNRY) saidit secured a contract with an undisclosed European country to supply its Imvanex smallpox vaccine in response to new cases of monkeypox in May. - Denmark-based Bavarian said its smallpox vaccine is approved in the U.S. as Jynneos and in Canada as Imvamune. In both countries the approval extends to cover the monkeypox indication. Bavarian Nordic stock jumps on smallpox vaccine Imvanex deal in Europe to fight monkeypox

The spread of monkeypox boosted the shares of Bavarian Nordic A/S, which says it's the only company to make a vaccine approved for the viral infection.

The monkeypox cases reported this month are evidence of chains of transmission of the virus, according to the European Centre for Disease Prevention and ...

Announcements at the second Global COVID-19 Summit included a technology licensing agreement for vaccine and diagnostic products developed by the US NIH, a new partnership to boost the use of testing and antiviral treatments in less wealthy countries, and a flurry of new funding pledges from organizations and companies alike. A report from industry federation EFPIA and its Vaccines Europe arm says that R&D has produced safe and effective tools for tackling COVID-19 but that the EU needs to address a set of short- to medium-term priorities if it is to be in a position to tackle future health emergencies. International regulators have issued an updated statement on the benefits and safety of COVID-19 vaccines for use by health professionals, while the UK BioIndustry Association has welcomed a MAb licensing deal between AstraZeneca and UK-based biotech firm RQ Bio.

Shares in Bavarian Nordic A/S jumped after the company received an order of its monkeypox vaccine from an “undisclosed European country.

The Danish company has the world's only licensed monkeypox vaccine and is now fielding enquiries from concerned governments from around the world.

Embattled gene therapy companies will take comfort from desire of FDA and EMA help smooth the process of bringing the novel treatments to market. FDA Leader: We Need To Remove Surprises From Gene Therapy Development We Need To Remove Surprises From Gene Therapy Development, Says US FDA’s Marks

The order will convert existing smallpox vaccines, which are also effective against monkeypox, into freeze-dried versions, which have a longer shelf life. The ...

You can select 'Manage settings' for more information and to manage your choices. You can change your choices at any time by visiting Your Privacy Controls. Find out more about how we use your information in our Privacy Policy and Cookie Policy. Click here to find out more about our partners. - Information about your device and internet connection, including your IP address

"The most recent BARDA purchase of smallpox vaccine was part of a standard and ongoing preparedness efforts and unrelated to specific events."

- "BARDA has worked with industry to develop and purchase vaccines and treatments for a potential smallpox emergency, some of which may also be used to respond to monkeypox," the spokesperson said. Driving the news: "The most recent BARDA purchase of smallpox vaccine was part of a standard and ongoing preparedness efforts and unrelated to specific events," an HHS spokesperson told Axios. The U.S. Biomedical Advanced Research and Development Authority's (BARDA) recent purchase of smallpox vaccines is not related to the new monkeypox outbreak, a spokesperson with the U.S. Department of Health and Human Services told Axios.